IP Library Patent Application 13144833
Patent Application
App. No. 13/144,833

ROSACEA TREATMENTS AND KITS FOR PERFORMING THEM

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/144,833
Abstract

Regimen for the treatment of rosacea include the application of an anti-redness composition to at least a portion of the cleansed area of skin afflicted with rosacea. The regimen may include the application of one or more of a polymetal complex, a composition containing metronidazole, and/or a protective composition. Kits containing components useful in performing such regimens are also described.

Claims (54)

1 . A treatment regimen comprising:

cleansing at least a portion of an area of skin afflicted with rosacea with an antimicrobial or cleanser;

applying an anti-redness composition to at least a portion of the cleansed area; and

applying a protective composition to at least a portion of the cleansed, and moisturized area.

2 . A treatment regimen as in claim 1 further comprising the step of applying a composition containing metronidazole to at least a portion of the afflicted area.

3 . A treatment regimen as in claim 1 wherein the protective composition comprises a sunscreen.

4 . A treatment regimen as in claim 1 wherein the protective composition comprises a compound selected from the group consisting of ZnO, Vitamin A, Vitamin D and combinations thereof.

5 . A treatment regimen as in claim 1 further comprising applying a benzoyl peroxide containing composition to at least a portion of the cleansed, and moisturized area of skin.

6 . A treatment regimen as in claim 1 further comprising applying a retinoid containing composition to at least a portion of the cleansed, moisturized area of skin.

7 . A treatment regimen as in claim 1 further comprising applying an antibiotic containing composition to at least a portion of the cleansed, and moisturized area of skin.

8 . The treatment method of claim 1 further comprising taking an oral antibiotic after applying the protective composition.

9 . A kit comprising:

a outer package enclosing individual containers containing

a cleanser;

an anti-redness composition; and

a protective composition.

10 . A treatment regimen comprising:

cleansing at least a portion of an area of skin afflicted with rosacea with an antimicrobial or cleanser;

applying a composition containing a polymetal complex to at least a portion of the cleansed area; and

applying a protective composition to at least a portion of the cleansed and polymetal complex-treated area.

11 . The treatment regimen as in claim 10 , further comprising applying a composition containing metronidazole to at least a portion of the afflicted area.

12 . The treatment regimen as in claim 10 further comprising applying to at least a portion of the afflicted area an additional ingredient selected from the group consisting of an anti-redness composition, an anti-parasitic compound, and combinations thereof.

13 . The treatment regimen of claim 12 , wherein the anti parasitic product is selected from the group consisting of benzyl benzoate, salicylic acid and combinations thereof.

14 . The treatment regimen as in claim 10 , wherein the polymetal complex comprises a Cu/Zn malonate complex.

15 . The treatment regimen as in claim 10 , wherein the protective composition comprises a sunscreen.

16 . The treatment regimen as in claim 10 , wherein the protective composition comprises a compound selected from the group consisting of ZnO, Vitamin A, Vitamin D and combinations thereof.

17 . The treatment regimen as in claim 10 , further comprising applying a benzoyl peroxide containing composition to at least a portion of the cleansed, and moisturized area of skin.

18 . The treatment regimen as in claim 10 , further comprising applying a retinoid containing composition to at least a portion of the cleansed, moisturized area of skin.

19 . The treatment regimen as in claim 10 , further comprising applying an antibiotic containing composition to at least a portion of the cleansed, and moisturized area of skin.

20 . The treatment method of claim 10 , further comprising taking an oral antibiotic after applying the protective composition.

21 . A kit comprising:

a cleanser;

a composition containing a polymetal complex; and

a protective composition.

22 . The kit as in claim 21 , further comprising a composition containing an additional ingredient selected from the group consisting of metronidazole, an anti-redness composition, an antibiotic, an anti-parasitic composition and combinations thereof.

23 . The kit as in claim 21 , wherein the composition containing a polymetal complex is a moisturizing composition.

24 . The kit as in claim 21 , wherein the protective composition is a sunscreen containing vitamins A and D.

25 . A method of treating skin afflicted with rosacea comprising the step of applying a redness reducing amount of a composition containing a polymetal complex to at least a portion of the afflicted area.

26 . The method of claim 25 , wherein the polymetal complex is a Cu/Zn malonate complex.

27 . The method of claim 25 , wherein the composition containing a polymetal complex further includes a moisturizer.

28 . The method of claim 25 , further comprising the step of cleansing at least a portion of the afflicted area.

29 . The method of claim 25 , wherein the cleanser is an antimicrobial cleanser.

30 . The method of claim 29 wherein the antimicrobial cleanser is selected from the group consisting of chlorhexidine gluconate, triclosan, zinc pyrithione, clindamycin phosphate, sodium sulphacetamide and combinations thereof.

31 . The method of claim 25 further comprising applying a protective composition to at least a portion of the afflicted area.

32 . The method of claim 31 wherein the protective composition comprises a sunscreen.

33 . The method of claim 31 wherein the sunscreen comprises a compound selected from the group consisting of ZnO, Vitamin A, Vitamin D and combinations thereof.

34 . The method of claim of claim 25 further comprising applying an anti-parasitic product to at least a portion of the afflicted area.

35 . The method of claim 34 wherein the anti-parasitic product includes a compound selected from the group consisting of benzyl benzoate, salicyclic acid and combinations thereof.

36 . The method of claim 25 further comprising applying an additional an anti-acne medication to at least a portion of the afflicted area.

37 . The method of claim 36 wherein the anti-acne medication is selected from the group consisting of benzoyl peroxide, retinoids, tetracycline, clindamycin, erythromycin, and combinations thereof.

38 . A method of treating skin afflicted with rosacea comprising sequentially applying a cleanser, an anti-redness composition, and a protective composition to at least a portion of the afflicted area.

39 . The method of claim of claim 38 further comprising applying a composition containing metronidazole to at least a portion of the afflicted area.

40 . The method of claim 38 further comprising applying an anti-acne medication to at least a portion of the afflicted area.

41 . The method of claim 40 wherein the anti-acne, medication is selected from the group consisting of benzoyl peroxide, retinoids, tetracycline, clindamycin, erythromycin, and combinations thereof.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2017
From: OBAGI MEDICAL PRODUCTS, INC.
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 044829/0092 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Nov 14, 2017
From: BARCLAYS BANK PLC
To: OBAGI MEDICAL PRODUCTS, INC.
Reel/Frame 044750/0475 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Nov 14, 2017
From: BANK OF NEW YORK MELLON
To: OBAGI MEDICAL PRODUCTS, INC.
Reel/Frame 044750/0506 →
SECURITY INTEREST Recorded Jul 19, 2017
From: OBAGI MEDICAL PRODUCTS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043041/0718 →
SECURITY INTEREST Recorded Jul 18, 2016
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSH & LOMB PHARMA HOLDINGS CORP.; DENDREON PHARMACEUTICALS, INC.; DOW PHARMACEUTICAL SCIENCES, INC.; MEDICIS PHARMACEUTICAL CORPORATION; OBAGI MEDICAL PRODUCTS, INC.; OMP, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; SOLTA MEDICAL, INC.; VALEANT CANADA LP, BY ITS GENERAL PARTNER VALEANT CANADA GP LIMITED; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT HOLDINGS IRELAND (AS SUCCESSOR TO VALEANT INTERNATIONAL BERMUDA); VALEANT PHARMACEUTICALS NORTH AMERICA LLC; VALEANT PHARMACEUTICALS IRELAND
To: BARCLAYS BANK PLC
Reel/Frame 039380/0385 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2016
From: RAMIREZ, JOSE E.; FARYNIARZ, JOSEPH R.; OUNANIAN, HOVIG
To: JR CHEM, LLC
Reel/Frame 037453/0971 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2016
From: JR CHEM, LLC
To: OBAGI MEDICAL PRODUCTS, INC.
Reel/Frame 037484/0104 →